Proton Pump Inhibitors Decrease Phlebotomy Need in HFE Hemochromatosis: Double-Blind Randomized Placebo-Controlled Trial

Annick Vanclooster, Cees van Deursen, Reggy Jaspers, David Cassiman, Ger Koek*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

21 Citations (Web of Science)


Phlebotomy constitutes the established treatment for HFE-related hemochromatosis. Retrospective studies have suggested proton pump inhibitors (PPIs) reduce the need for phlebotomy in this population. We conducted a randomized controlled trial to prove this. Thirty p.C282Y homozygous patients were randomly allocated to PPI (pantoprazole 40 mg/day) or placebo for 12 months. Phlebotomies were performedwhen serum ferritin was >100 mu g/L. Phlebotomy need turned out to be significantly lower in patients taking PPI (P = .0052). PPI treatment significantly reduces the need for phlebotomies in p.C282Y homozygous patients. In view of the known long-term safety profile of PPI, they can be a valuable addition to standard therapy.

Original languageEnglish
Pages (from-to)678-680.e2
Number of pages5
Issue number3
Publication statusPublished - Sept 2017


  • Hereditary Hemochromatosis
  • Proton Pump Inhibitors
  • Randomized Clinical Trial
  • IRON

Cite this